ALLO Latest Headlines

ALLO-329’s Dual CAR T Approach Targets Autoimmune Disease Market with Preclinical Success

Market Chameleon (Thu, 16-Apr 11:14 AM)

ALLO Gears Up for Key Interim Data Release on Pivotal Phase 2 ALPHA3 Trial—What Should Investors Watch Ahead of April 13?

Market Chameleon (Mon, 13-Apr 11:55 AM)

Interim ALPHA3 Trial Data Shows 58.3% MRD Clearance for ALLO’s Cema-cel in Large B-Cell Lymphoma

Market Chameleon (Mon, 13-Apr 8:23 AM)